Veterinary Vaccine Market, by Technology (Inactivated Vaccines, Toxoid Vaccines, Live Attenuated Vaccines, and Subunit and DNA Vaccines), by Animal Type (Companion (Equine, Canine, and Feline) and Livestock (Bovine, Ovine, Porcine, Poultry, and Others)),

Veterinary Vaccine Market, by Technology (Inactivated Vaccines, Toxoid Vaccines, Live Attenuated Vaccines, and Subunit and DNA Vaccines), by Animal Type (Companion (Equine, Canine, and Feline) and Livestock (Bovine, Ovine, Porcine, Poultry, and Others)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Veterinary/Animal vaccines are parenteral products that are used as prophylactic as well as in the treatment of various veterinary diseases. Veterinary vaccines play a crucial role in ensuring good health, longevity, and improving overall productivity of pets and livestock, in a cost-effective manner. It also plays an important role in curtailing incidence of transmission of various diseases from animals to humans.
Vaccines are broadly classified as inactivated vaccines, toxoid vaccines, live attenuated vaccines, conjugated vaccines, and subunit and DNA vaccines. Veterinary vaccines impact animal health and production quality and also ensure good health of general human population through consumption of various food procured from animals. The continued interaction between animals and health professionals are the major importance for adaption of novel technologies in heath sector.
Market Dynamics
Increasing incidence of veterinary diseases is expected to drive the veterinary vaccine market growth during the forecast period. For instance, according to the 2015 Global Animal Disease Intelligence Report by the Food and Agriculture Organization (FAO), prevalence of foot-and-mouth disease (FMD) was high in Morocco, Saudi Arabia, Turkey, Northern, and Southern Africa. Ebola (Zoonotic disease) continued to be prevalent in West Africa. Moreover, rabies that leads to thousands of human deaths worldwide is prevalent in 150 countries, according to the WHO, with highest number of related deaths reported in Asia and Africa.
Key features of the study:
This report provides in-depth analysis of the veterinary vaccine market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global veterinary vaccine market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
Key players covered as a part of this study include Aratana Therapeutics, Inc., Regeneus Ltd., Morphogenesis, Inc., Karyopharm Therapeutics, Inc., Zoetis, Inc., Eli Lilly and Company, Merck & Co., Inc., and Boehringer Ingelheim GmbH.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, government initiatives, technological upgradation, market expansion, and marketing tactics
The global veterinary vaccine market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for veterinary vaccine market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Veterinary Vaccine Market, By Technology:
Inactivated Vaccines
Toxoid Vaccine
Live Attenuated Vaccines
Subunit and DNA Vaccines
Global Veterinary Vaccine Market, By Animal Type:
Companion
Equine
Canine
Feline
Livestock
Bovine
Ovine
Porcine
Poultry
Others
Global Veterinary Vaccine Market, By Region:
North America
By Country:
U.S.
Canada
By Technology:
Inactivated Vaccines
Toxoid Vaccine
Live Attenuated Vaccines
Subunit and DNA Vaccines
By Animal Type:
Companion
Equine
Canine
Feline
Livestock
Bovine
Ovine
Porcine
Poultry
Others
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Technology:
Inactivated Vaccines
Toxoid Vaccine
Live Attenuated Vaccines
Subunit and DNA Vaccines
By Animal Type:
Companion
Equine
Canine
Feline
Livestock
Bovine
Ovine
Porcine
Poultry
Others
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Technology:
Inactivated Vaccines
Toxoid Vaccine
Live Attenuated Vaccines
Subunit and DNA Vaccines
By Animal Type:
Companion
Equine
Canine
Feline
Livestock
Bovine
Ovine
Porcine
Poultry
Others
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Technology:
Inactivated Vaccines
Toxoid Vaccine
Live Attenuated Vaccines
Subunit and DNA Vaccines
By Animal Type:
Companion
Equine
Canine
Feline
Livestock
Bovine
Ovine
Porcine
Poultry
Others
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Technology:
Inactivated Vaccines
Toxoid Vaccine
Live Attenuated Vaccines
Subunit and DNA Vaccines
By Animal Type:
Companion
Equine
Canine
Feline
Livestock
Bovine
Ovine
Porcine
Poultry
Others
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Technology:
Inactivated Vaccines
Toxoid Vaccine
Live Attenuated Vaccines
Subunit and DNA Vaccines
By Animal Type:
Companion
Equine
Canine
Feline
Livestock
Bovine
Ovine
Porcine
Poultry
Others
Company Profiles
Aratana Therapeutics, Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Regeneus Ltd.
Morphogenesis, Inc.
Karyopharm Therapeutics, Inc.
Zoetis, Inc.
Eli Lilly and Company
Merck & Co., Inc.
Boehringer Ingelheim GmbH
“*” marked represents similar segmentation in other categories in the respective section.